Microarc oxidized TiO2 based ceramic coatings combined with cefazolin sodium/chitosan composited drug film on porous titanium for biomedical applications.

Microarc oxidized TiO2 based ceramic coatings combined with cefazolin sodium/chitosan composited drug film on porous titanium for biomedical applications.

Materials science & engineering. C, Materials for biological applications (2013-08-06)

Daqing Wei, Rui Zhou, Su cheng, Wei Feng, Baoqiang Li, Yaming Wang, Dechang Jia, Yu Zhou, Haifeng Guo

ABSTRACT

Porous titanium was prepared by pressureless sintering of titanium beads with diameters of 100, 200, 400 and 600 μm. The results indicated that the mechanical properties of porous titanium changed significantly with different bead diameters. Plastic deformations such as necking phenomenon and dimple structure were observed on the fracture surface of porous titanium sintered by beads with diameter of 100 μm. However, it was difficult to find this phenomenon on the porous titanium with a titanium bead diameter of 600 μm. The microarc oxidized coatings were deposited on its surface to improve the bioactivity of porous titanium. Furthermore, the cefazolin sodium/chitosan composited films were fabricated on the microarc oxidized coatings for overcoming the inflammation due to implantation, showing good slow-release ability by addition of chitosan. And the release kinetic process of cefazolin sodium in composited films could be possibly fitted by a polynomial model.

MATERIALS

Product Number

Brand

Product Description

204730

Sigma-Aldrich

Titanium(IV) oxide, rutile, 99.995% trace metals basis

204757

Sigma-Aldrich

Titanium(IV) oxide, rutile, ≥99.98% trace metals basis

224227

Sigma-Aldrich

Titanium(IV) oxide, rutile, powder, <5 μm, ≥99.9% trace metals basis

700355

Sigma-Aldrich

Titanium(IV) oxide, mixture of rutile and anatase, nanoparticle, <250 nm particle size (DLS), paste, 53-57 wt. % in diethylene glycol monobutyl ether/ethylene glycol, 99.9% trace metals basis

700347

Sigma-Aldrich

Titanium(IV) oxide, mixture of rutile and anatase, nanoparticles, <150 nm particle size (volume distribution, DLS), dispersion, 40 wt. % in H₂O, 99.5% trace metals basis

634662

Sigma-Aldrich

Titanium(IV) oxide, mixture of rutile and anatase, nanopowder, <100 nm particle size (BET), 99.5% trace metals basis

637262

Sigma-Aldrich

Titanium(IV) oxide, rutile, nanopowder, <100 nm particle size, 99.5% trace metals basis

700339

Sigma-Aldrich

Titanium(IV) oxide, mixture of rutile and anatase, nanoparticles, <100 nm particle size, dispersion, 48-52 wt. % in xylene, 99.9% trace metals basis

635065

Sigma-Aldrich

Titanium(IV) oxide, rutile, <110>, single crystal substrate, ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm

635057

Sigma-Aldrich

Titanium(IV) oxide, rutile, <001>, (single crystal substrate), ≥99.9% trace metals basis, L × W × thickness 10 mm × 10 mm × 0.5 mm

C0682800

Cefazolin, European Pharmacopoeia (EP) Reference Standard

1097603

USP

Cefazolin, United States Pharmacopeia (USP) Reference Standard

718467

Sigma-Aldrich

Titanium(IV) oxide, nanopowder, 21 nm primary particle size (TEM), ≥99.5% trace metals basis

677469

Sigma-Aldrich

Titanium(IV) oxide, contains 1% Mn as dopant, nanopowder, <100 nm particle size (BET), ≥97%

248576

Sigma-Aldrich

Titanium(IV) oxide, anatase, powder, −325 mesh, ≥99% trace metals basis

232033

Sigma-Aldrich

Titanium(IV) oxide, anatase, powder, 99.8% trace metals basis

C5020

Sigma-Aldrich

Cefazolin sodium salt, 89.1-110.1%

14021

Sigma-Aldrich

Titanium(IV) oxide, ReagentPlus^®, ≥99%

14027

Sigma-Aldrich

Titanium(IV) oxide, puriss., meets analytical specification of Ph. Eur., BP, USP, 99-100.5%

637254

Sigma-Aldrich

Titanium(IV) oxide, anatase, nanopowder, <25 nm particle size, 99.7% trace metals basis